Developer docs
API playgroundTry for free, no card

Search company profiles

iRhythm Technologies

Full company profile

uuid0000jpx

Namestring
iRhythm Technologies
Legal namestring
iRhythm Technologies, Inc.
Websiteurl
irhythmtech.com
Company typeenum
Public
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ambulatory cardiac monitoring, ECG patch devices, cardiac arrhythmia detection, AI-powered ECG analysis, mobile cardiac telemetry
Industry5 codes
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Other Measuring and Controlling Device Manufacturing334519
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Monitoring Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Zio Monitor Services
TypeSubscription Recurring
Description

iRhythm provides ambulatory cardiac monitoring services through its Zio platform. Revenue is generated through billing for technical component (CPT 93243/93247 for Zio monitor) and interpretation services. The company bills insurance for the technical component while physicians bill for interpretation.

fool.com
2Zio AT Mobile Cardiac Telemetry
TypeSubscription Recurring
Description

Mobile cardiac telemetry services billed under CPT code 93229 (technical component) and 93228 (interpretation). Provides continuous recording with wear-time transmissions and comprehensive end-of-wear reports.

irhythmtech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Pricing details2 tiers
1Zio Monitor - Technical Component
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Billed by iRhythm under CPT 93243 (>48 hours up to 7 days) or CPT 93247 (>7 days up to 15 days). Insurance-dependent pricing.

irhythmtech.com
2Zio AT - Technical Component
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Billed by iRhythm under CPT 93229. External mobile cardiovascular telemetry with ECG recording for up to 30 days.

irhythmtech.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Zio
Description

Ambulatory cardiac monitoring platform including Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry)

irhythmtech.com
+5 more records
Core offering1 text field

iRhythm Technologies provides ambulatory cardiac monitoring services through its Zio platform, combining single-use wearable ECG biosensors (Zio monitor and Zio AT) with an FDA-cleared deep-learned AI algorithm (ZEUS) and Qualified Cardiac Technician review. The service delivers continuous cardiac rhythm recording for up to 14 days, AI-assisted arrhythmia detection across 13 arrhythmia classes, and physician-ready end-of-wear reports with 99% physician agreement, distributed via the ZioSuite clinician portal, MyZio patient app, and integrated EHR workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 2x more likely to result in specified arrhythmia diagnoses compared to Holter monitoring
+7 more records
Product overview1 text field

iRhythm Technologies offers a unified cardiac monitoring platform centered on its Zio brand of ECG monitoring products and services. The core portfolio consists of the Zio monitor (long-term continuous monitoring up to 14 days) and Zio AT (mobile cardiac telemetry with real-time transmissions), both single-use wearable ECG patches. These devices are supported by the ZioSuite clinician portal (web and mobile app for patient management and report interpretation), the MyZio patient app (for symptom logging and patient support), and EHR integration services connecting with Epic, Cerner, Athena, Meditech, eClinicalWorks, and 450+ other systems via HL7 and Epic Aura network. The platform's intelligence is powered by the FDA-cleared ZEUS deep-learned AI algorithm, which analyzes continuous ECG data to detect 13 arrhythmia types with cardiologist-level accuracy, verified by Qualified Cardiac Technicians to generate physician-ready reports with 99% physician agreement. The service also includes Home Enrollment capabilities for at-home monitor application and the iRhythm Academy education platform for healthcare professionals.

Product and service6 records
1Zio Monitor
CategoryLong-Term Continuous Cardiac Monitor
Description

Single-use, prescription-only ambulatory ECG monitor that continuously records cardiac data for up to 14 days. iRhythm's thinnest and lightest long-term continuous monitoring (LTCM) device with breathable, pliable, waterproof housing designed for patient comfort and 99% patient compliance. Delivers highest diagnostic yield of specified arrhythmia diagnoses compared to other monitoring services and is intended for cardiology, electrophysiology, and primary care prescribing physicians.

2Zio AT
CategoryMobile Cardiac Telemetry Service
Description

Mobile cardiac telemetry (MCT) monitoring device providing continuous, uninterrupted ECG recording with real-time wear-time transmissions and comprehensive end-of-wear reporting. Single-use monitor with proprietary hydrogel electrodes and a patented flexible, lightweight, water-resistant design requiring no maintenance or battery changes. Achieves 98% patient compliance and 99% analyzable time, and is intended for clinicians requiring real-time cardiac telemetry for at-risk patients.

3ZioSuite
CategoryClinician Portal and Mobile Platform
Description

Secure web portal and mobile app for healthcare professionals enabling patient enrollment, device tracking, online report interpretation, and account management. HIPAA-compliant, end-to-end encrypted, FIPS 140-2 validated, and SOC 2 Type 2 certified, with iOS and Android availability and a Dual Interpretation feature supporting fellowship training workflows. Sold as part of the Zio monitoring service for clinicians and institutions managing enrolled patients.

4MyZio Patient App
CategoryPatient Mobile Application
Description

Mobile companion app for patients wearing Zio ECG monitors, supporting digital symptom logging (with users 4.3x more likely to record symptoms vs. paper log), educational content, wear-time reminders, monitor return prompts, and home enrollment tracking. Available in English and Spanish with 1+ million downloads, distributed as part of the Zio service for patient engagement.

5EHR Integration Service
CategoryEHR Integration and Interoperability Service
Description

Technical integration service enabling Zio orders and results to flow directly through electronic health record systems, including HL7 Version 2.3+ and Epic Aura network connectivity. Delivers discrete data for 195+ fields supporting structured reporting, population health management, and analytics, compatible with Epic, Cerner, Athena, Meditech, eClinicalWorks, and 450+ other EHR systems. Sold to healthcare provider organizations as part of deploying the Zio monitoring service.

6iRhythm Monitoring Service
CategoryEnd-to-End Cardiac Monitoring Service
Description

End-to-end cardiac monitoring service bundling Zio ECG monitors, the FDA-cleared ZEUS deep-learned AI algorithm, Qualified Cardiac Technician review, ZioSuite portal, MyZio patient app, and EHR integration. Delivers physician-ready reports with 99% physician agreement and is sold to cardiology practices, hospitals, health systems, primary care physicians, and health plans seeking accurate arrhythmia diagnosis.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership where Heartbeat Health's virtual cardiology practice provides comprehensive diagnostics and care planning alongside iRhythm's cardiac monitoring solutions. The partnership enables enhanced arrhythmia detection to virtual cardiology expertise, empowering care teams to enhance outcomes, streamline workflows, and drive results.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership announced July 2025 to introduce a predictive AI solution for early detection of arrhythmias in patient populations with comorbid conditions. Combines iRhythm's cardiac monitoring with Lucem Health's predictive analytics capabilities.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Senko Medical representatives distribute iRhythm's Zio ambulatory ECG monitoring services in Japan. The partnership enabled the May 2025 launch of Zio Long-Term Continuous Monitoring Service in Japan with PMDA-approved deep-learning AI.

Strategic tierCoreTypeTechnology or Integration
Description

iRhythm is the first medical device company to offer services through Epic's Aura network, enabling seamless and secure transmission of Zio orders and results. Provides one-time seamless setup with prebuilt orders and questions.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GE Healthcare is a broad incumbent in cardiology diagnostics (ECG carts, MUSE cardiology information systems, hospital patient monitoring). Competes with iRhythm indirectly at the health system level through integrated diagnostic suites rather than as a focused ambulatory patch specialist.

TypeEmerging player
Description

Eko Health combines digital stethoscopes with AI algorithms for cardiac and pulmonary disease detection. Overlaps with iRhythm in AI-driven cardiac diagnostics and primary care screening use cases, though Eko focuses on point-of-care rather than long-duration patch monitoring.

TypeDirect peer
Description

AliveCor makes KardiaMobile, a consumer and clinical single-lead ECG device with AI-based AFib detection, overlapping with iRhythm's short-duration and at-home screening use cases. Targets primary care, cardiology, and health plan channels similar to iRhythm's emerging GTM.

TypeDirect peer
Description

Boston Scientific owns Preventice Solutions (BodyGuardian), a wearable cardiac monitoring service offering MCT, event, and Holter patches. Direct competitor in ambulatory ECG services with overlap in Zio AT's mobile cardiac telemetry category.

TypeDirect peer
Description

Philips acquired BioTelemetry, a leading provider of ambulatory cardiac monitoring services (event, Holter, MCT). Direct competitor to iRhythm's Zio service in the same hospital, cardiology practice, and IDN customer base using similar CPT-coded reimbursement pathways.

TypeEmerging player
Description

Huxley Medical is an early-stage company developing AI-enabled wearable cardiac monitoring devices aimed at ambulatory arrhythmia detection. Directly comparable to iRhythm's patch-based LTCM service with potential overlap in cardiology and primary care channels.

TypeBroad incumbent
Description

Baxter (which acquired Hillrom) offers hospital-based cardiac monitoring, ECG carts, and connected care platforms. Competes with iRhythm at the inpatient and ambulatory boundary, particularly for telemetry and continuous monitoring workflows in hospitals.

TypeBroad incumbent
Description

Medtronic's cardiac diagnostics portfolio includes LINQ insertable cardiac monitors (ICM) and remote monitoring services, competing indirectly with Zio in long-term arrhythmia detection while offering broader cardiac rhythm management including pacemakers and ICDs.

TypeRegional player
Description

HeartFlow offers AI-driven coronary CT-derived FFR analysis for cardiovascular disease diagnosis, complementary to but not directly competing with iRhythm's arrhythmia monitoring. Shares the same cardiology customer base and AI-enabled cardiac diagnostics positioning.

10Abbott (Cardiac Diagnostics)
TypeBroad incumbent
Description

Abbott's cardiovascular franchise includes the Confirm Rx insertable cardiac monitor and CardiioMEMS heart failure diagnostics. Competes with iRhythm in long-duration cardiac monitoring, particularly for patients with infrequent or hard-to-capture arrhythmias.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iRhythm Technologies

Cardiac Monitoring Servicesirhythmtech.com

iRhythm Technologies firmographics

Firmographics
Name
iRhythm Technologies
Legal name
iRhythm Technologies, Inc.
Website
https://irhythmtech.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

iRhythm Technologies industry classification

Industry
Product category
Cardiac Monitoring Services
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Other Measuring and Controlling Device Manufacturing (334519)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Ambulatory cardiac monitoring
  • ECG patch devices
  • Cardiac arrhythmia detection
  • AI-powered ECG analysis
  • Mobile cardiac telemetry

Where iRhythm Technologies is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

iRhythm Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Zio Monitor Services: iRhythm provides ambulatory cardiac monitoring services through its Zio platform. Revenue is generated through billing for technical component (CPT 93243/93247 for Zio monitor) and interpretation services. The company bills insurance for the technical component while physicians bill for interpretation.
  2. Zio AT Mobile Cardiac Telemetry: Mobile cardiac telemetry services billed under CPT code 93229 (technical component) and 93228 (interpretation). Provides continuous recording with wear-time transmissions and comprehensive end-of-wear reports.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goZio Monitor - Technical Component
Unit PricingPay-as-you-goZio AT - Technical Component

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

iRhythm Technologies product offering

Product offering

Core offering

iRhythm Technologies provides ambulatory cardiac monitoring services through its Zio platform, combining single-use wearable ECG biosensors (Zio monitor and Zio AT) with an FDA-cleared deep-learned AI algorithm (ZEUS) and Qualified Cardiac Technician review. The service delivers continuous cardiac rhythm recording for up to 14 days, AI-assisted arrhythmia detection across 13 arrhythmia classes, and physician-ready end-of-wear reports with 99% physician agreement, distributed via the ZioSuite clinician portal, MyZio patient app, and integrated EHR workflows.

Product overview

iRhythm Technologies offers a unified cardiac monitoring platform centered on its Zio brand of ECG monitoring products and services. The core portfolio consists of the Zio monitor (long-term continuous monitoring up to 14 days) and Zio AT (mobile cardiac telemetry with real-time transmissions), both single-use wearable ECG patches. These devices are supported by the ZioSuite clinician portal (web and mobile app for patient management and report interpretation), the MyZio patient app (for symptom logging and patient support), and EHR integration services connecting with Epic, Cerner, Athena, Meditech, eClinicalWorks, and 450+ other systems via HL7 and Epic Aura network. The platform's intelligence is powered by the FDA-cleared ZEUS deep-learned AI algorithm, which analyzes continuous ECG data to detect 13 arrhythmia types with cardiologist-level accuracy, verified by Qualified Cardiac Technicians to generate physician-ready reports with 99% physician agreement. The service also includes Home Enrollment capabilities for at-home monitor application and the iRhythm Academy education platform for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

  • Zio: Ambulatory cardiac monitoring platform including Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry)
  • ZioSuite
  • MyZio
  • ZEUS
  • Know Your Rhythm
  • iRhythm Academy

Products and services

  • Zio Monitor Single-use, prescription-only ambulatory ECG monitor that continuously records cardiac data for up to 14 days. iRhythm's thinnest and lightest long-term continuous monitoring (LTCM) device with breathable, pliable, waterproof housing designed for patient comfort and 99% patient compliance. Delivers highest diagnostic yield of specified arrhythmia diagnoses compared to other monitoring services and is intended for cardiology, electrophysiology, and primary care prescribing physicians.
  • Zio AT Mobile cardiac telemetry (MCT) monitoring device providing continuous, uninterrupted ECG recording with real-time wear-time transmissions and comprehensive end-of-wear reporting. Single-use monitor with proprietary hydrogel electrodes and a patented flexible, lightweight, water-resistant design requiring no maintenance or battery changes. Achieves 98% patient compliance and 99% analyzable time, and is intended for clinicians requiring real-time cardiac telemetry for at-risk patients.
  • ZioSuite Secure web portal and mobile app for healthcare professionals enabling patient enrollment, device tracking, online report interpretation, and account management. HIPAA-compliant, end-to-end encrypted, FIPS 140-2 validated, and SOC 2 Type 2 certified, with iOS and Android availability and a Dual Interpretation feature supporting fellowship training workflows. Sold as part of the Zio monitoring service for clinicians and institutions managing enrolled patients.
  • MyZio Patient App Mobile companion app for patients wearing Zio ECG monitors, supporting digital symptom logging (with users 4.3x more likely to record symptoms vs. paper log), educational content, wear-time reminders, monitor return prompts, and home enrollment tracking. Available in English and Spanish with 1+ million downloads, distributed as part of the Zio service for patient engagement.
  • EHR Integration Service Technical integration service enabling Zio orders and results to flow directly through electronic health record systems, including HL7 Version 2.3+ and Epic Aura network connectivity. Delivers discrete data for 195+ fields supporting structured reporting, population health management, and analytics, compatible with Epic, Cerner, Athena, Meditech, eClinicalWorks, and 450+ other EHR systems. Sold to healthcare provider organizations as part of deploying the Zio monitoring service.
  • iRhythm Monitoring Service End-to-end cardiac monitoring service bundling Zio ECG monitors, the FDA-cleared ZEUS deep-learned AI algorithm, Qualified Cardiac Technician review, ZioSuite portal, MyZio patient app, and EHR integration. Delivers physician-ready reports with 99% physician agreement and is sold to cardiology practices, hospitals, health systems, primary care physicians, and health plans seeking accurate arrhythmia diagnosis.

Quantifiable outcome

  • 2x more likely to result in specified arrhythmia diagnoses compared to Holter monitoring
  • +7 more outcomes

Companies that use iRhythm Technologies

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

iRhythm Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability3 records

Feature5 records

iRhythm Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Heartbeat HealthcoreStrategic or Co-development PartnerPartnership where Heartbeat Health's virtual cardiology practice provides comprehensive diagnostics and care planning alongside iRhythm's cardiac monitoring solutions. The partnership enables enhanced arrhythmia detection to virtual cardiology expertise, empowering care teams to enhance outcomes, streamline workflows, and drive results.
  • Lucem HealthcoreStrategic or Co-development PartnerPartnership announced July 2025 to introduce a predictive AI solution for early detection of arrhythmias in patient populations with comorbid conditions. Combines iRhythm's cardiac monitoring with Lucem Health's predictive analytics capabilities.
  • Senko Medical (泉工医科工業)coreChannel Partner/ Reseller/ DistributorSenko Medical representatives distribute iRhythm's Zio ambulatory ECG monitoring services in Japan. The partnership enabled the May 2025 launch of Zio Long-Term Continuous Monitoring Service in Japan with PMDA-approved deep-learning AI.
  • Epic (via Aura Network)coreTechnology or IntegrationiRhythm is the first medical device company to offer services through Epic's Aura network, enabling seamless and secure transmission of Zio orders and results. Provides one-time seamless setup with prebuilt orders and questions.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

iRhythm Technologies competitors and assessment

Company assessment

Broad incumbents

  • GE Healthcare (incl. MUSE and patient monitoring): GE Healthcare is a broad incumbent in cardiology diagnostics (ECG carts, MUSE cardiology information systems, hospital patient monitoring). Competes with iRhythm indirectly at the health system level through integrated diagnostic suites rather than as a focused ambulatory patch specialist.
  • Hillrom / Baxter (now part of Baxter): Baxter (which acquired Hillrom) offers hospital-based cardiac monitoring, ECG carts, and connected care platforms. Competes with iRhythm at the inpatient and ambulatory boundary, particularly for telemetry and continuous monitoring workflows in hospitals.
  • Medtronic (Cardiac Diagnostics): Medtronic's cardiac diagnostics portfolio includes LINQ insertable cardiac monitors (ICM) and remote monitoring services, competing indirectly with Zio in long-term arrhythmia detection while offering broader cardiac rhythm management including pacemakers and ICDs.
  • Abbott (Cardiac Diagnostics): Abbott's cardiovascular franchise includes the Confirm Rx insertable cardiac monitor and CardiioMEMS heart failure diagnostics. Competes with iRhythm in long-duration cardiac monitoring, particularly for patients with infrequent or hard-to-capture arrhythmias.

Emerging players

  • Eko Health: Eko Health combines digital stethoscopes with AI algorithms for cardiac and pulmonary disease detection. Overlaps with iRhythm in AI-driven cardiac diagnostics and primary care screening use cases, though Eko focuses on point-of-care rather than long-duration patch monitoring.
  • Huxley Medical: Huxley Medical is an early-stage company developing AI-enabled wearable cardiac monitoring devices aimed at ambulatory arrhythmia detection. Directly comparable to iRhythm's patch-based LTCM service with potential overlap in cardiology and primary care channels.

Direct peers

  • AliveCor: AliveCor makes KardiaMobile, a consumer and clinical single-lead ECG device with AI-based AFib detection, overlapping with iRhythm's short-duration and at-home screening use cases. Targets primary care, cardiology, and health plan channels similar to iRhythm's emerging GTM.
  • Boston Scientific (Preventice Solutions): Boston Scientific owns Preventice Solutions (BodyGuardian), a wearable cardiac monitoring service offering MCT, event, and Holter patches. Direct competitor in ambulatory ECG services with overlap in Zio AT's mobile cardiac telemetry category.
  • Philips (BioTelemetry): Philips acquired BioTelemetry, a leading provider of ambulatory cardiac monitoring services (event, Holter, MCT). Direct competitor to iRhythm's Zio service in the same hospital, cardiology practice, and IDN customer base using similar CPT-coded reimbursement pathways.

Regional players

  • HeartFlow: HeartFlow offers AI-driven coronary CT-derived FFR analysis for cardiovascular disease diagnosis, complementary to but not directly competing with iRhythm's arrhythmia monitoring. Shares the same cardiology customer base and AI-enabled cardiac diagnostics positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

iRhythm Technologies social profiles

Digital presence

iRhythm Technologies compliance and trust

Trust signal

Compliance4 records

iRhythm Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iRhythm Technologies leadership team

Management profile

Number of profiles

Profiles14 records

iRhythm Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

iRhythm Technologies funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iRhythm Technologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iRhythm Technologies

What does iRhythm Technologies do?

iRhythm Technologies provides ambulatory cardiac monitoring services through its Zio platform, combining single-use wearable ECG biosensors (Zio monitor and Zio AT) with an FDA-cleared deep-learned AI algorithm (ZEUS) and Qualified Cardiac Technician review. The service delivers continuous cardiac rhythm recording for up to 14 days, AI-assisted arrhythmia detection across 13 arrhythmia classes, and physician-ready end-of-wear reports with 99% physician agreement, distributed via the ZioSuite clinician portal, MyZio patient app, and integrated EHR workflows.

Is iRhythm Technologies a public or private company?

iRhythm Technologies is a public company. It is classified as public and is currently operating.

When was iRhythm Technologies founded?

iRhythm Technologies was founded in 2006. It employs 1,001 to 5,000 people.

Where is iRhythm Technologies based?

iRhythm Technologies is headquartered in San Francisco, United States, in the North America region.

How does iRhythm Technologies make money?

Two revenue lines are on record. Zio Monitor Services are the primary driver. The others are zio AT Mobile Cardiac Telemetry.

Who are iRhythm Technologies's main competitors?

Broad incumbents on record are GE Healthcare (incl. MUSE and patient monitoring), Hillrom / Baxter (now part of Baxter), Medtronic (Cardiac Diagnostics) and Abbott (Cardiac Diagnostics). Emerging players are Eko Health and Huxley Medical. Direct peers are AliveCor, Boston Scientific (Preventice Solutions) and Philips (BioTelemetry). HeartFlow is listed as a regional player.

Does iRhythm Technologies have an API?

No public API is recorded for iRhythm Technologies.

What industry is iRhythm Technologies in?

iRhythm Technologies's product category is Cardiac Monitoring Services. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerIRhythm Signs $100 Million Accelerated Share BuybackiRhythm entered an accelerated share buyback agreement with JPMorgan Chase for $100 million, as part of its $200 million authorization. The company will fund the buyback with existing cash and cash equivalents, with final settlement expected by the first quarter of 2027. After completion, about $100 million will remain in the buyback authorization program.MorningstariRhythm Signs $100 Million Accelerated Share BuybackiRhythm entered an accelerated share buyback agreement with JPMorgan Chase for $100 million, receiving about 80% of shares upfront. The company will fund it with existing cash, with final settlement expected by the first quarter of 2027. After completion, about $100 million will remain in its buyback authorization.MarketWatchiRhythm Signs $100M Accelerated Share BuybackiRhythm entered an accelerated share buyback agreement with JPMorgan Chase for $100 million, as part of its $200 million authorization. The company will fund the buyback with existing cash and cash equivalents, with final settlement expected by the first quarter of 2027.TradingViewiRhythm Holdings to Repurchase $100 Million of Stock Through Accelerated BuybackiRhythm Holdings entered a $100 million accelerated share repurchase agreement with JPMorgan under its $200 million buyback program. The company will pay $100 million upfront for about 80% of expected shares, with final settlement expected in the first quarter of 2027, funded with existing cash.Seeking AlphaiRhythm kicks off $100M accelerated share repurchase deal with JPMorganiRhythm announced a $100M accelerated share repurchase with JPMorgan under its $200M buyback authorization, paying $100M upfront for about 80% of expected shares. Final settlement is expected by Q1 2027, with remaining shares determined by the stock's volume-weighted average price. Approximately $100M will remain available under the authorization.American Banking and Market NewsStock Buyback Plan Declared by iRhythm Technologies (NASDAQ:IRTC) Board of DirectorsiRhythm Technologies' board authorized a $200 million share buyback, allowing repurchase of up to 6.7% of its stock. The company reported Q3 EPS of $0.82, beating estimates, with revenue of $221.59 million, up 14.9% year-over-year.FinancialContent Business PageIRHYTHM HOLDINGS, INC. INVESTIGATION: IRTC Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsKirby McInerney LLP is investigating potential securities law violations against iRhythm Holdings, prompted by the company's Q3 2026 results. Revenue of $221.6 million missed consensus, and the company delayed Zio MCT's FDA filing to 2027, causing a 30.7% share drop. No lawsuit has been filed yet.Simply Wall StiRhythm (IRTC) Stock May Look Reasonable Despite An Investor InvestigationiRhythm Holdings' stock has fallen 46.6% year to date, prompting a review of whether its sales justify the current valuation. The stock trades at a P/S of 3.7x, below the peer group's 4.9x but above the sector average of 2.7x, and the Fair Ratio model suggests it is undervalued. Recent revenue shortfalls and a delayed device submission have already priced in some of the discount.The future of tradingiRhythm Adopts Deferred Compensation Plan for Employees and Directors Effective January 2027iRhythm Holdings adopted a nonqualified deferred compensation plan effective January 1, 2027, covering employees and non-employee directors. Eligible employees may defer up to 80% of base salary and 100% of bonuses, while directors may defer 100% of cash fees. The plan is unfunded, leaving participants as unsecured general creditors.